SCHEMBL4022229

SCHEMBL4022229

COC(=O)CS(=O)(=O)c1ccc(C)cc1

nearest known ligand 0.62

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.62
KMT2A Q03164 3/20 0.56
RECQL P46063 1/20 0.56
CA2 P00918 3/20 0.53
CA9 Q16790 3/20 0.53
CA12 O43570 2/20 0.53
CA1 P00915 2/20 0.53
PKM P14618 1/20 0.53
HSD11B1 P28845 1/20 0.51
MAPT P10636 2/20 0.51
HSD17B10 Q99714 1/20 0.51
CYP3A4 P08684 2/20 0.50
CYP2C9 P11712 2/20 0.50
CYP2C19 P33261 2/20 0.50
CYP1A2 P05177 1/20 0.50
LMNA P02545 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10967679 0.85 ALDH1A1 (0.54) ALDH1A1KMT2ARECQLCA2CA9
SCHEMBL1346520 0.84 ALDH1A1 (0.65) ALDH1A1KMT2ACA2CA9CA12
SCHEMBL2178479 0.84 KMT2A (0.78) ALDH1A1KMT2ARECQLCA2CA9
SCHEMBL17550651 0.84 GAA (0.53) ALDH1A1KMT2ACA2CA9CA12
SCHEMBL13299623 0.84 PLCG1 (0.52) ALDH1A1KMT2ARECQLCA2CA1
SCHEMBL2069531 0.84 SMN1; SMN2 (0.52) ALDH1A1KMT2ACA2CA9CA12
SCHEMBL1346537 0.84 HTT (0.58) ALDH1A1KMT2ACA2CA1PKM
SCHEMBL602 0.83 HSD11B1 (0.59) ALDH1A1KMT2AHSD11B1MAPTHSD17B10
SCHEMBL23049753 0.82 KMT2A (0.53) ALDH1A1KMT2ACA2
SCHEMBL3282087 0.82 ALDH1A1 (0.64) ALDH1A1KMT2ARECQLCA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114213266-A Synthesis process of high-purity D-N- (2, 6-xylyl) alanine methyl ester 浙江禾本科技股份有限公司 2022-03-22 CN claimed
CN-120988477-B Microporous high-magnification polyethersulfone foam material for electromagnetic shielding and mould pressing foaming preparation method thereof 东营瑞致新材料有限公司 2026-04-14 CN disclosed
CN-120988477-A Microporous high-magnification polyethersulfone foam material for electromagnetic shielding and mould pressing foaming preparation method thereof 东营瑞致新材料有限公司 2025-11-21 CN disclosed
WO-2024217500-A1 ISOQUINOLINE COMPOUND, AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF 上海赛默罗生物科技有限公司 2024-10-24 WO disclosed
CN-114213266-B Synthesis process of high-purity D-N- (2, 6-xylyl) alanine methyl ester 浙江禾本科技股份有限公司 2023-11-10 CN disclosed
US-20230321016-A1 COMBINATION THERAPY FOR TREATING CANCER GONGWIN BIOPHARM CO., LTD (TW) 2023-10-12 US disclosed
US-11752160-B2 Method for reducing fat by administering benzenesulfonamide compositions GONGWIN BIOPHARM CO., LTD (TW) 2023-09-12 US disclosed
US-11752118-B2 Method for treating melanoma GONGWIN BIOPHARM CO., LTD (TW) 2023-09-12 US disclosed
CN-111212833-B Phenylpyridine derivatives and pharmaceutical compositions containing the same 株式会社大熊制药 2022-09-06 CN disclosed
EP-3696176-B1 NOVEL PHENYLPYRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME DAE WOONG PHARMA (KR) 2022-05-04 EP disclosed
US-20170172951-A1 NOVEL PHARMACEUTICAL COMPOSITIONS OF BENZENESULFONAMIDE DERIVATIVES FOR TREATMENT OF ADENOID CYSTIC CARCINOMA GONGWIN BIOPHARM CO., LTD. (TAIWAN) (TW) 2017-06-22 US disclosed
US-20170045820-A1 RESIST UNDERLAYER FILM-FORMING COMPOSITION AND METHOD FOR FORMING RESIST PATTERN USING THE SAME NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2017-02-16 US disclosed
CN-101023089-B Silane merocyanine sulphone derivatives, photoprotecting compositions containing same, use thereof as UV filter OREAL 2013-11-06 CN disclosed
US-7510703-B2 UV-photoprotecting/sunscreen compositions comprising silane/siloxane derivatives of merocyanine sulfones L'OREAL (FR) 2009-03-31 US disclosed
US-20070224147-A1 UV-photoprotecting/sunscreen compositions comprising silane/siloxane derivatives of merocyanine sulfones L'OREAL (FR) 2007-09-27 US disclosed
CN-101023089-A Silane merocyanine sulphone derivatives, photoprotecting compositions containing same, use thereof as UV filter OREAL (FR) 2007-08-22 CN disclosed
US-7244859-B2 Method for producing δ-aminopentadienoate derivatives FUJIFILM CORPORATION (JP) 2007-07-17 US disclosed
EP-0111997-B1 VINYL CARBOXYLIC ACID DERIVATIVES, THEIR PRODUCTION AND USE Takeda Chemical Industries, Ltd. (JP) 1991-04-10 EP disclosed
US-4518602-A Vinyl carboxylic acid derivatives, their production and use as inhibitors of thromboxane synthetase TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1985-05-21 US disclosed
EP-0111997-A2 Vinyl carboxylic acid derivatives, their production and use Takeda Chemical Industries, Ltd. (JP) 1984-06-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170172951-A1 NOVEL PHARMACEUTICAL COMPOSITIONS OF BENZENESULFONAMIDE DERIVATIVES FOR TREATMENT OF ADENOID CYSTIC CARCINOMA ABCD3, CFTR, ADSL ALDH1A1 1243/4885KMT2A 3531/4885RECQL 31/4885
US-11752160-B2 Method for reducing fat by administering benzenesulfonamide compositions LIPE, FABP4, LIPA ALDH1A1 728/4885KMT2A 2032/4885RECQL 1843/4885
US-20070224147-A1 UV-photoprotecting/sunscreen compositions comprising silane/siloxane derivatives of merocyanine sulfones ERCC1, ERCC5, CRY1 ALDH1A1 227/4885KMT2A 2703/4885RECQL 1275/4885
US-20230321016-A1 COMBINATION THERAPY FOR TREATING CANCER TP53, MCL1, TOP2B ALDH1A1 381/4885KMT2A 1380/4885RECQL 390/4885
US-11752118-B2 Method for treating melanoma TYR, MITF, BRAF ALDH1A1 528/4885KMT2A 1442/4885RECQL 49/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.